A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas.

MLA

Kumthekar, Priya, et al. “A Phase II Trial of Arsenic Trioxide and Temozolomide in Combination with Radiation Therapy for Patients with Malignant Gliomas.” Journal of Neuro-Oncology, vol. 133, no. 3, July 2017, pp. 589–94. EBSCOhost, https://doi.org/10.1007/s11060-017-2469-x.

APA

Kumthekar, P., Grimm, S., Chandler, J., Mehta, M., Marymont, M., Levy, R., Muro, K., Helenowski, I., McCarthy, K., Fountas, L., & Raizer, J. (2017). A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas. Journal of Neuro-Oncology, 133(3), 589–594. https://doi.org/10.1007/s11060-017-2469-x

Chicago

Kumthekar, Priya, Sean Grimm, James Chandler, Minesh Mehta, Maryanne Marymont, Robert Levy, Kenji Muro, et al. 2017. “A Phase II Trial of Arsenic Trioxide and Temozolomide in Combination with Radiation Therapy for Patients with Malignant Gliomas.” Journal of Neuro-Oncology 133 (3): 589–94. doi:10.1007/s11060-017-2469-x.